CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Catalyst Pharmaceuticals (CPRX) reported positive Phase I results for Agamree, suggesting its potential for new indications beyond Duchenne muscular dystrophy (DMD). The study indicated that Agamree offers corticosteroid benefits with less immunosuppression compared to PTC Therapeutics' Emflaza, which could lead to its use in other chronic inflammatory rare diseases. This development is significant as Catalyst Pharmaceuticals is in the process of being acquired by Angelini Pharma for $4.1 billion, with the deal expected to close in Q3 2026.
CPRX - Catalyst Pharmaceuticals Inc Earnings
This article provides a detailed financial overview of Catalyst Pharmaceuticals Inc. (CPRX), including its latest stock performance, key financial metrics, earnings data, and insider/institutional ownership. It highlights the company's strong growth in sales and EPS over various periods and offers analyst recommendations.
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE® conducted by its North American partner, Catalyst Pharmaceuticals. The study in healthy adult volunteers showed that AGAMREE® delivers glucocorticoid and anti-inflammatory activity with less pronounced immunosuppressive biomarker effects at clinical doses, suggesting potential for treating a broad range of chronic inflammatory rare diseases. Significant immunosuppressive effects were only observed at the highest dose levels, exceeding currently approved AGAMREE® dosing for Duchenne muscular dystrophy.
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE® conducted by Catalyst Pharmaceuticals, indicating the drug's potential for broad chronic inflammatory rare diseases by demonstrating glucocorticoid and anti-inflammatory activity without significant immunosuppressive effects at therapeutic doses. The study found AGAMREE® to have comparable cortisol suppression to deflazacort at clinical doses but with less pronounced immunosuppressive biomarker effects. This supports its differentiated safety profile observed in long-term studies for Duchenne muscular dystrophy (DMD), where it showed advantages in bone health and growth compared to conventional corticosteroids.
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Santhera Pharmaceuticals has announced topline results from a Phase 1 clinical study of AGAMREE® conducted by its North American partner, Catalyst Pharmaceuticals. The study in healthy volunteers indicates that AGAMREE® delivers glucocorticoid and anti-inflammatory activity with minimal immunosuppressive effects, suggesting its potential for treating various chronic inflammatory rare diseases. These findings support its current use for Duchenne muscular dystrophy and future indications, with findings showing immunosuppressive effects only at doses higher than those approved.
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression
Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 study of vamorolone in healthy volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no significant immunosuppressive activity at clinical doses, supporting its current dosing for Duchenne muscular dystrophy. These findings suggest vamorolone could be a differentiated treatment option for a wide range of chronic inflammatory rare diseases by providing anti-inflammatory benefits without the typical immunosuppression of conventional corticosteroids.
Vamorolone Demonstrates On-Target Glucocorticoid Activity
Catalyst Pharmaceuticals, Inc. announced positive topline results from a Phase 1 clinical study of vamorolone in healthy adult volunteers. The study showed that vamorolone delivers on-target glucocorticoid and anti-inflammatory activity with expected cortisol suppression, but without significant immunosuppression at clinical doses. These findings suggest vamorolone distinguishes itself from traditional corticosteroids and has potential for treating various chronic inflammatory rare diseases.
Catalyst's rare-disease steroid showed immune activity without the usual suppression
Catalyst Pharmaceuticals announced positive topline results from a Phase 1 study of vamorolone in healthy adults, demonstrating on-target glucocorticoid activity with expected cortisol suppression and without significant immunosuppression at clinical doses. The study compared vamorolone to deflazacort, showing similar cortisol suppression but less pronounced immunosuppressive effects for vamorolone. These findings support vamorolone's potential use in Duchenne muscular dystrophy (DMD) and other chronic inflammatory rare diseases by offering anti-inflammatory benefits without the typical immune-suppressing side effects of conventional corticosteroids.
Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In
Catalyst Pharmaceuticals (CPRX) has generated significant investor interest due to its strong rare-disease portfolio, which produced substantial annual revenue and net income. While the current share price of $31.42 is close to an external target, cash flow estimates suggest a 50% discount to its intrinsic value, implying potential upside. However, its P/E ratio is slightly above the industry average, raising questions about whether future growth is already priced in.
Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX
This article provides access to the "Price to earnings forward" financial data for Catalyst Pharmaceuticals, Inc. (CPRX) on the Nasdaq Stock Market. It's presented through the TradingView platform, which offers various financial tools and market data services. The content emphasizes accessing specific financial metrics for the company.
Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX
This article displays information regarding the enterprise value to revenue forward for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It provides a snapshot of the company's financial data on TradingView. The content is primarily a data point without extensive analytical text.
Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX
This article provides the "Price to sales forward" financial metric for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It is presented within a financial data platform from TradingView, which also lists other company information and market data services. The content itself seems focused on delivering this specific financial data point.
Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026
As of June 15, 2026, Catalyst Pharmaceuticals (CPRX) had 7.95 million shares sold short, representing 7.25% of its public float, marking a 2.91% decrease from the previous report. The short interest ratio is 5.5 days to cover. This data indicates a slight decrease in bearish sentiment for CPRX among investors.
Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger
Catalyst Pharmaceuticals (NasdaqCM:CPRX) has received early U.S. Federal Trade Commission clearance for its proposed merger with Angelini Pharma, accelerating the regulatory review process. This clearance addresses a major regulatory hurdle for the acquisition, which is still contingent on shareholder approval and is expected to close in Q3 2026. The merger will see Catalyst operate as a wholly-owned subsidiary of Angelini, shifting the investment focus for Catalyst shareholders from long-term independent growth to a defined cash outcome.
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is scrutinizing whether the offered price of $31.50 per share adequately values the company and if the sales process was fair to shareholders. KSF encourages shareholders who believe the offer undervalues Catalyst Pharmaceuticals to contact them for a discussion regarding their legal rights.
Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger – Key Details from 8-K Filing
Catalyst Pharmaceuticals, Inc. has announced a definitive merger agreement with Angelini Pharma S.p.A., where Catalyst will become a wholly-owned subsidiary of Angelini Pharma. The all-cash transaction is expected to close in the third quarter of 2026, subject to customary closing conditions and shareholder approval. This merger is considered a significant, price-sensitive event for Catalyst shareholders, who are urged to review all SEC filings, especially the Definitive Proxy Statement, for important details regarding their investment.
Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026
Catalyst Pharmaceuticals announced that the FTC granted early termination of the HSR waiting period for its merger with Angelini Pharma. This regulatory clearance, granted on June 16, 2026, paves the way for the merger, which is expected to close in Q3 2026, subject to customary closing conditions and stockholder approval. Investors are urged to review the Definitive Proxy Statement filed with the SEC on June 8, 2026, for detailed information.
HSR waiting period ends for Catalyst (NASDAQ: CPRX) and Angelini Pharma merger
The U.S. Federal Trade Commission has granted early termination of the Hart-Scott-Rodino (HSR) antitrust waiting period for Catalyst Pharmaceuticals' planned acquisition by Angelini Pharma. This clearance removes a significant U.S. antitrust hurdle for the merger, which was agreed upon on May 6, 2026. The transaction is still contingent on approval by Catalyst's shareholders and other customary closing conditions, with an expected closing in the third quarter of 2026.
Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares
Analysts maintain a Hold rating for Catalyst Pharmaceuticals (CPRX) with a consensus 12-month price target of $31.50, aligning with its current trading level. The company, which specializes in rare neuromuscular and neurological diseases, recently reported adjusted earnings of $0.79 per share, exceeding the Zacks consensus estimate. Despite a 42% one-year performance and a market capitalization of $3.8 billion, analysts see limited upside at present.
Catalyst Pharmaceuticals Inc (CPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Catalyst Pharmaceuticals Inc (CPRX), focusing on its price momentum, support, resistance levels, indicators, and moving averages. As of June 24, 2026, CPRX has a price momentum score of 4.85, indicating it is suitable for range-bound swing trading between resistance at $31.49 and support at $31.29. The technical indicators suggest a "Buy" signal, with most moving averages also indicating a strong "Buy."
Catalyst Pharmaceuticals Inc (CPRX) Institutional Confidence
Catalyst Pharmaceuticals Inc (CPRX) has an institutional shareholding score of 10.00, ranking first in the Pharmaceuticals industry. The institutional shareholding proportion is 90.33%, showing a quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 1.92% of outstanding shares.
Catalyst Pharmaceuticals Inc (CPRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Catalyst Pharmaceuticals Inc (CPRX), outlining major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent changes in holdings by key institutions. The report also lists ETFs with stakes in CPRX.
Catalyst Pharmaceuticals Inc (CPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides details on Catalyst Pharmaceuticals Inc. (CPRX), including its current stock price, market capitalization, and P/E ratio. It states that the company has not yet disclosed relevant data regarding its revenue breakdown by business segment or region. The article primarily serves as a placeholder for this financial information.
Catalyst Pharmaceuticals Inc (CPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Catalyst Pharmaceuticals Inc (CPRX), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that CPRX's score of 6.40 ranks 130 out of 157 in the Pharmaceuticals industry, with analysts setting an average price target of $34.00. The company's expected revenue for the next quarter is $155.32 million, and its EPS for the next quarter is expected to be $0.48.
Catalyst Pharmaceuticals Inc (CPRX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Catalyst Pharmaceuticals Inc (CPRX) by TradingKey. It reports that CPRX has a current valuation score of 7.03, ranking 140 out of 157 in the Pharmaceuticals industry, with a P/E ratio of 17.38. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
The Technical Signals Behind (CPRX) That Institutions Follow
This article analyzes Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) using AI models to identify technical signals and institutional trading strategies. It notes a neutral near and mid-term outlook with a longer-term positive bias, and provides specific position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis. The report highlights potential upside given no resistance levels remain above the current price.
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax
Catalyst Pharmaceuticals' Chief Medical Officer, William T. Andrews, reported the exercise of 3,052 restricted stock units (RSUs) into common stock. Of these, 743 shares were withheld for tax obligations, leaving him with a direct holding of 2,309 shares. The RSUs vest in equal annual tranches from 2026 to 2030.
Catalyst Pharmaceuticals (CPRX) 10K Form and Latest SEC Filings 2026
This article provides an overview of Catalyst Pharmaceuticals' (CPRX) SEC filings, including its 10K forms, 8K current reports, and Form 4 insider ownership changes. It highlights the importance of these filings for investors to access verified financial data and track company events and insider trading activity. The most recent filing was a Form 4 submitted on June 5, 2026, detailing an ownership change.
Precision Trading with Catalyst Pharmaceuticals Inc. (CPRX) Risk Zones
Quantitative Research Desk has published an analysis on Catalyst Pharmaceuticals Inc. (CPRX), identifying neutral near and mid-term readings but a potentially moderating long-term positive bias. The report offers three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels, and emphasizes sophisticated risk management. No clear price positioning signal was identified, but the absence of resistance levels above the current price suggests compelling upside potential.
Precision Trading with Catalyst Pharmaceuticals Inc. (CPRX) Risk Zones
This article provides a detailed AI-driven analysis of Catalyst Pharmaceuticals Inc. (CPRX) stock, outlining various trading strategies for different risk profiles. It highlights neutral near and mid-term readings but a positive long-term bias, and offers specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies. The analysis emphasizes the utilization of predictive AI for optimizing trading decisions and managing risk.
CPRX PE Ratio & Valuation, Is CPRX Overvalued
This article analyzes the valuation of Catalyst Pharmaceuticals Inc (CPRX), determining it to be undervalued. Based on its forward PE ratio of 12.87 compared to a five-year average of 14.23, and a current price of $31.27 versus a fair price range of $41.66 to $58.16, CPRX is considered undervalued by 24.94%. The analysis also details its Price-to-Book ratio, Free Cash Flow yield, and compares its Price-to-Sales ratio against competitors.
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Hold Rating, Maintains Target Price $31.5
H.C. Wainwright has reiterated its Hold rating for Catalyst Pharmaceuticals (CPRX.US) and maintained its target price at $31.5. This indicates a consistent outlook on the company's stock value from the analyst firm.
H.C. Wainwright Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5
H.C. Wainwright has downgraded Catalyst Pharmaceuticals (CPRX.US) from a Buy to a Hold rating. The firm also significantly cut its price target for CPRX from $84 to $31.5. This downgrade suggests a more cautious outlook on the company's stock performance.
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Stock Forecast & Analyst Predictions
This article provides an in-depth analysis of Catalyst Pharmaceuticals (CPRX), including its market cap, future growth forecasts, recent earnings, insider transactions, and major announcements. Analysts predict earnings and revenue growth, though slower than the broader US market, with a strong return on equity. Key recent developments include a potential acquisition by Angelini Pharma and settlements of FIRDAPSE patent litigation, both significantly impacting the company's future trajectory.
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals (CPRX)
NULL
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. (CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash. The investigation aims to determine if Catalyst's board of directors violated federal securities laws or breached fiduciary duties by failing to secure the best price, conduct a fair sales process, or disclose all material information to shareholders. Halper Sadeh LLC represents investors globally and may seek increased consideration or additional disclosures on behalf of affected shareholders.
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story
Catalyst Pharmaceuticals has agreed to an all-cash acquisition by Angelini Pharma and settled all Firdapse patent litigation, granting generic licenses through 2035. This deal provides an exit strategy for current public shareholders and positions Catalyst’s rare disease portfolio within a larger pharmaceutical group, changing its narrative from independent growth to integration. Investors should monitor transaction terms, closing timelines, and how the combined entity will position its rare disease portfolio.
Catalyst Pharmaceuticals, Inc. - Common Stock (NQ: CPRX)
This article provides a list of recent news headlines, press releases, and research articles related to Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX). It covers financial results, analyst ratings, acquisition news, patent litigation settlements, and conference participations, spanning from December 2025 to May 2026. The stock was trading at 31.18, up 0.02 (+0.06%) as of 4:00 PM EDT, May 15, 2026.
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y
Catalyst Pharmaceuticals reported first-quarter earnings that surpassed expectations, with Firdapse revenues showing year-over-year growth. This financial performance indicates a positive start to the year for the company, largely driven by its key drug.
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus
Angelini Pharma is reportedly considering an acquisition of Catalyst Pharmaceuticals (NasdaqCM:CPRX), focusing attention on Catalyst's rare disease portfolio and market valuation. While early discussions are underway and Angelini is exploring other targets, this potential deal highlights Catalyst's attractiveness and could significantly impact its share price depending on the certainty of funding and deal terms. Investors are advised to monitor official confirmations and how the share price reacts to periods of silence, as the current valuation may reflect M&A expectations.
Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives
Catalyst Pharmaceuticals (CPRX) reported strong Q1 2026 results with revenues of US$149.4 million and EPS of US$0.52, maintaining a high net profit margin of 37.1%. While bullish narratives highlight durable margins from rare disease drugs like FIRDAPSE and AGAMREE, concerns exist regarding slower earnings growth (12.1% annually against 32.6% over five years) and heavy reliance on a few key products, which could face competition and pressure future profitability. The stock currently trades at a P/E of 17.2x, below the industry average and a DCF fair value of US$64.46, leading to a split in investor sentiment.
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Catalyst Pharmaceuticals reported strong Q1 2026 earnings, beating analyst estimates with adjusted earnings of 79 cents per share and total revenues of $149.4 million. The growth was primarily driven by Firdapse sales, which increased 18% year over year, and the newer drug Agamree. The company also announced a settlement for Firdapse patent litigation and is set to be acquired by Angelini Pharma for approximately $4.1 billion, reinforcing Angelini's focus on neurological diseases.
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, Vs. FactSet Est of $0.65
Catalyst Pharmaceuticals, Inc. (CPRX) announced its Q1 adjusted earnings per share (EPS) of $0.79, significantly exceeding FactSet's estimate of $0.65 per share. This financial performance indicates a stronger-than-anticipated quarter for the company.
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Reports Q1 Revenue $149.4M, vs. FactSet Est of $149.5M
Catalyst Pharmaceuticals, Inc. (CPRX) reported its Q1 revenue at $149.4 million, slightly below FactSet's estimate of $149.5 million. The company is a biopharmaceutical firm focused on developing medicines for rare and difficult-to-treat diseases, marketing products like FIRDAPSE, FYCOMPA, and AGAMREE. This earnings flash provides a quick overview of their financial performance for the first quarter.
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
Catalyst Pharmaceuticals reported strong first-quarter 2026 financial results, with total Q1 2026 net product revenue reaching $149.3 million, a 5.6% year-over-year increase. The growth was primarily driven by FIRDAPSE® and AGAMREE®, which saw revenue increases of 18.1% and 66.6% respectively. The company also reported $755.9 million in cash and cash equivalents and no funded debt as of March 31, 2026.
Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives
Catalyst Pharmaceuticals (CPRX) reported strong Q1 2026 results with US$149.4 million in revenue and a basic EPS of US$0.52, reinforcing its high net profit margin of 37.1%. While bullish narratives highlight durable margins from products like FIRDAPSE and AGAMREE, bears point to slowing earnings growth and dependence on a few key drugs, raising concerns about future profitability and potential margin pressure from competition or generics. The stock trades at a P/E of 17.2x, below the US Biotechs industry average, with a discounted cash flow (DCF) fair value of US$64.46, indicating a potential undervaluation if growth and margins can be sustained.
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is examining whether the offering price of $31.50 per share adequately values the company and if the process leading to the transaction was fair to shareholders. Shareholders are encouraged to contact KSF to discuss their legal rights regarding the proposed sale.
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum
Catalyst Pharmaceuticals (CPRX) has shown strong share price momentum recently. The stock trades at a P/E of 17.8x, which is considered good value against peers but slightly expensive compared to its estimated fair P/E of 15.1x. A Discounted Cash Flow (DCF) model suggests a fair value almost double the current price, indicating a potential significant undervaluation.
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in cash. KSF is scrutinizing whether this acquisition price and the process leading to it adequately value the company. Shareholders who believe the transaction undervalues Catalyst Pharmaceuticals are encouraged to contact KSF to discuss their legal rights.
Angelini Pharma buying Catalyst (NASDAQ: CPRX) in $4.1B all-cash deal at premium
Angelini Pharma will acquire Catalyst Pharmaceuticals (NASDAQ: CPRX) in an all-cash deal valued at approximately $4.1 billion, or $31.50 per share, representing a significant premium. This acquisition marks Angelini Pharma's entry into the U.S. market, aiming to strengthen its presence in brain health and rare diseases. Additionally, Catalyst settled patent litigation for its drug FIRDAPSE®, securing U.S. market exclusivity for its generic version until January 2035.
